← Back to Search

HEMOTAG with Standard of Care in DM patients for Type 2 Diabetes (PRIZETAG Trial)

N/A
Recruiting
Research Sponsored by Aventusoft, LLC.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights

Summary

To evaluate the proportion of diabetic mellitus patients with CV events as measured by HEMOTAG.

Eligible Conditions
  • Type 2 Diabetes
  • Stroke
  • Peripheral Arterial Disease
  • Coronary Artery Disease
  • Cardiovascular Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
To evaluate the proportion of diabetic mellitus patients with cardiovascular events as identified by HEMOTAG measurements over a 12 month duration.
Secondary study objectives
All Deaths for 12 months
Correlation of AO and CE at 6 and 12 months
Correlation of CTI and CE at 6 and 12 months
+6 more
Other study objectives
All cause hospitalizations
Health Status as measured by the LVD-36
Health care resource utilization
+2 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: HEMOTAG with Standard of Care in DM patientsExperimental Treatment1 Intervention
HEMOTAG with Standard of Care: To evaluate the proportion of diabetic mellitus patients with cardiovascular events as identified by HEMOTAG measurements over a 12 month duration.

Find a Location

Who is running the clinical trial?

National Heart, Lung, and Blood Institute (NHLBI)NIH
3,889 Previous Clinical Trials
47,834,092 Total Patients Enrolled
Aventusoft, LLC.Lead Sponsor
1 Previous Clinical Trials
420 Total Patients Enrolled
~126 spots leftby Mar 2026